SEC Form 4 · accession 0001209191-18-043125
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Jul 16, 2018
Accepted (ET)
Jul 18, 2018 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 16, 2018 | M | 23,375 | $131.89 | A | 62,488 | D | |
| Common StockF2,F3 | Jul 16, 2018 | S | 23,375 | $182.00 | D | 39,113 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $131.89 | Jul 16, 2018 | M | 23,375 | D | — | Jul 20, 2025 | Common Stock | 23,375 | 10,625 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Altshuler's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $182.00 (range $181.89 to $182.16).
- F3Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4The option vests in 16 quarterly installments from 7/21/2015.